Last reviewed · How we verify
Non selective beta blocker - Propranolol
Non selective beta blocker - Propranolol is a Small molecule drug developed by Hadassah Medical Organization. It is currently in Phase 2 development.
Propranolol is a non-selective beta blocker used to treat various conditions, including liver cirrhosis, portal hypertension, and acute kidney injury, as seen in clinical trials on ClinicalTrials.gov. It is often used as a monotherapy or in combination with other medications, such as rifaximin, to manage these conditions.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Non selective beta blocker - Propranolol |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MEdical Treatment in Idiopathic Ventricular Fibrillation Patients (PHASE4)
- Pre-emptive RTO for An Early Detected Gastric Varices in CT/MR Angiogram Trial (NA)
- A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease (NA)
- Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design
- Role of Non-Selective Beta-Adrenergic Blocker in Severe TBI (PHASE3)
- The Treatment of Hepatocirrhosis and Portal Hypertension (NA)
- Propranolol Adjuvant Treatment of Focal Refractory Epilepsy (PATFRE) (EARLY_PHASE1)
- Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non selective beta blocker - Propranolol CI brief — competitive landscape report
- Non selective beta blocker - Propranolol updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI
Frequently asked questions about Non selective beta blocker - Propranolol
What is Non selective beta blocker - Propranolol?
Who makes Non selective beta blocker - Propranolol?
What development phase is Non selective beta blocker - Propranolol in?
Related
- Manufacturer: Hadassah Medical Organization — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing